Bionano Genomics (NASDAQ:BNGO) Now Covered by Analysts at HC Wainwright

Stock analysts at HC Wainwright began coverage on shares of Bionano Genomics (NASDAQ:BNGO) in a research report issued on Wednesday,Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 253.36% from the company’s current price.

Separately, Scotiabank lifted their price objective on shares of Bionano Genomics from $1.00 to $4.00 and gave the stock a “sector perform” rating in a research report on Wednesday, April 2nd.

Bionano Genomics Trading Down 4.1 %

Shares of Bionano Genomics stock opened at $2.83 on Wednesday. The stock has a fifty day moving average price of $4.22 and a 200-day moving average price of $12.15. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99. The firm has a market cap of $8.51 million, a PE ratio of -0.02 and a beta of 2.08. Bionano Genomics has a 1 year low of $2.68 and a 1 year high of $72.60.

Institutional Trading of Bionano Genomics

A number of institutional investors have recently modified their holdings of BNGO. Jane Street Group LLC bought a new position in shares of Bionano Genomics in the fourth quarter worth $118,000. Geode Capital Management LLC grew its position in shares of Bionano Genomics by 47.3% during the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after purchasing an additional 283,639 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Bionano Genomics in the fourth quarter worth $46,000. XTX Topco Ltd bought a new stake in Bionano Genomics during the fourth quarter valued at $45,000. Finally, Carret Asset Management LLC grew its position in Bionano Genomics by 39.9% during the fourth quarter. Carret Asset Management LLC now owns 119,000 shares of the company’s stock worth $34,000 after buying an additional 33,945 shares in the last quarter. 11.35% of the stock is currently owned by hedge funds and other institutional investors.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.